<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989010</url>
  </required_header>
  <id_info>
    <org_study_id>LS-CLDN18.2 001</org_study_id>
    <nct_id>NCT04989010</nct_id>
  </id_info>
  <brief_title>Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors</brief_title>
  <official_title>Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET-CT Imaging in Patients With CLDN18.2 Positive Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuxi No. 4 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuxi No. 4 People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled&#xD;
      anti-CLDN18.2 mAbs (89Zr-NY005) PET imaging in patients with CLDN18.2 positive solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being fully informed about the study and potential risks, all patients giving written&#xD;
      informed consent will be evaluated to determine eligibility for study entry. Patients will&#xD;
      receive an injection of anti-CLDN18.2 mAbs(89Zr-NY005) and will undergo PET/CT scanning to&#xD;
      determine uptake of 89Zr-NY005 in tumor lesions and normal tissues and organs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of tissue distribution of 89Zr-Anti-CLDN18.2 mAbs(NY005)</measure>
    <time_frame>1 year</time_frame>
    <description>Biodistribution of 89Zr-Anti-CLDN18.2 mAbs (NY005) evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 89Zr-PET scans will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic analysis of 89Zr-Anti-CLDN18.2 mAbs (NY005).</measure>
    <time_frame>1 year</time_frame>
    <description>Area under the radioactivity (SUVs) versus time (time from injection) curve (AUC) will be derived by integration and reported.&#xD;
Other pharmacokinetic parameters including peak radioactive uptake (Cmax) and time (Tmax) in different organs, clearance and volume of distribution, evaluated using a biexponential model and non-compartmental analysis, will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosimetry estimates of 89Zr-Anti-CLDN18.2 mAbs (NY005).</measure>
    <time_frame>1 year</time_frame>
    <description>Absorbed dose (radioactive uptake) estimates for different organs and tissues calculated with the AUCs and the OLINDA/EXM dosimetry program will be obtained and reported.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>89Zr-NY005 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3 mCi) labeled anti-CLDN18.2 mAbs (89Zr-NY005)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>89Zr-NY005</intervention_name>
    <description>89Zr-NY005 injection followed by 89Zr-NY005 PET scan</description>
    <arm_group_label>89Zr-NY005 injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients voluntarily signed informed consent, and be able to complete the trial&#xD;
             according to the requirement of the scheme;&#xD;
&#xD;
          2. Aged 18-80, male or female;&#xD;
&#xD;
          3. The clinical diagnosis was gastric cancer, esophageal cancer and pancreatic cancer;&#xD;
&#xD;
          4. Patients with biopsy-proven CLDN18.2 positive;&#xD;
&#xD;
          5. Patients diagnosed with solid tumors confirmed by histopathology or cytology test;&#xD;
&#xD;
          6. At least two measurable solid lesions has been examined by 18F-FDG PET/CT (RECIST1.1&#xD;
             standard);&#xD;
&#xD;
          7. ECOG score â‰¤ 0~3; Life expectancy of at least 3 months;&#xD;
&#xD;
          8. ALT, AST shall not exceed 3 times of the normal upper limit; Bun, Cr not exceed 1.5&#xD;
             times of the normal upper limit.&#xD;
&#xD;
          9. Other routine examinations are within the normal range or considered acceptable by the&#xD;
             researchers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recovery from major trauma (including surgery) within 4 weeks prior to study&#xD;
             treatment;&#xD;
&#xD;
          2. Patients with systemic or locally severe infections, or other serious coexisting&#xD;
             diseases;&#xD;
&#xD;
          3. Patients with abnormal immune function or who have recently used immunosuppressive or&#xD;
             potentiating agents including various vaccines;&#xD;
&#xD;
          4. Patients with autoimmune diseases, including rheumatoid arthritis;&#xD;
&#xD;
          5. Inadequate control of arrhythmias, including atrial fibrillation;&#xD;
&#xD;
          6. Uncontrolled hypertension;&#xD;
&#xD;
          7. Patients with allergies or allergies to any component of the imaging agent or&#xD;
             antibody;&#xD;
&#xD;
          8. Patients who cannot undergo PET/CT imaging scan;&#xD;
&#xD;
          9. Syphilis, HBV, HCV, or HIV positive subjects;&#xD;
&#xD;
         10. Male and female subjects of reproductive age cannot take effective contraceptive&#xD;
             measures;&#xD;
&#xD;
         11. Pregnant or lactating women;&#xD;
&#xD;
         12. Patients with a history of mental illness or related conditions;&#xD;
&#xD;
         13. Other subjects considered unsuitable by researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wuxi No. 4 People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214062</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chunjing Yu, MD.</last_name>
      <phone>15312238622</phone>
      <email>ycj_wxd1978@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

